Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Short Interest Update

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 73,800 shares, a decline of 47.8% from the October 15th total of 141,400 shares. Based on an average daily trading volume, of 80,700 shares, the short-interest ratio is presently 0.9 days.

Ekso Bionics Price Performance

Shares of EKSO stock remained flat at $0.77 during midday trading on Wednesday. The company’s stock had a trading volume of 98,017 shares, compared to its average volume of 115,603. Ekso Bionics has a one year low of $0.74 and a one year high of $3.13. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The stock has a 50-day simple moving average of $1.05 and a 200 day simple moving average of $1.12. The firm has a market capitalization of $16.92 million, a PE ratio of -1.18 and a beta of 1.47.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The firm had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same quarter last year, the business earned ($0.24) earnings per share. Analysts anticipate that Ekso Bionics will post -0.48 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC lifted its holdings in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the period. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.42% of the company’s stock.

Analyst Ratings Changes

EKSO has been the subject of several research analyst reports. HC Wainwright decreased their price objective on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. StockNews.com began coverage on shares of Ekso Bionics in a research report on Monday. They set a “hold” rating on the stock. Finally, Lake Street Capital reduced their target price on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, October 29th.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.